Patents by Inventor J.H. Frederik Falkenburg

J.H. Frederik Falkenburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF
    Publication number: 20240009235
    Abstract: Novel nucleic acid compositions, vector systems, modified cells and pharmaceutical compositions that encode or express T cell receptor components directed against Bob 1 are provided herein. These novel components may be used to enhance an immune response in a subject diagnosed with a hyperproliferative disease or condition. Associated methods for treating such subjects are therefore also provided herein.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 11, 2024
    Inventors: Mirjam H.M. HEEMSKERK, J.H. Frederik FALKENBURG
  • TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
    Publication number: 20220305102
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 29, 2022
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LEIDS UNIVERSITAIR MEDISCH CENTRUM)
    Inventors: Marieke GRIFFIOEN, J. H. Frederik FALKENBURG
  • Treatment of haematological malignancies
    Patent number: 11352389
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 7, 2022
    Assignee: Academisch Ziekenhuis Leiden (h.o.d.n. Leids Universitair Medisch Centrum)
    Inventors: Marieke Griffioen, J. H. Frederik Falkenburg
  • BINDING PROTEINS SPECIFIC FOR HA-1H AND USES THEREOF
    Publication number: 20210380656
    Abstract: Novel nucleic acid compositions, vectors, modified cells and pharmaceutical compositions are provided that are useful for treating or preventing a relapse of a haematological malignancy after allogeneic stem cell transplantation (allo-SCT) in a HLA-A*0201 positive human subject. Corresponding methods and uses are also provided.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 9, 2021
    Inventors: Mirjam H.M. HEEMSKERK, J.H. Frederik FALKENBURG
  • TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
    Publication number: 20200123200
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM 1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Application
    Filed: June 28, 2018
    Publication date: April 23, 2020
    Inventors: Marieke GRIFFIOEN, J. H. Frederik FALKENBURG
  • T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF
    Publication number: 20200054678
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against the Preferentially Expressed Antigen of Melanoma (PRAME). Provided are methods for treating hyperproliferative diseases by inducing an immune response against PRAME antigen; the immune response may be induced by specifically targeting PRAME-expressing cells using T cell receptors directed against PRAME.
    Type: Application
    Filed: July 24, 2019
    Publication date: February 20, 2020
    Inventors: Mirjam H.M. Heemskerk, J.H. Frederik Falkenburg
  • T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF
    Publication number: 20190233485
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Application
    Filed: December 7, 2018
    Publication date: August 1, 2019
    Inventors: Mirjam H.M HEEMSKERK, J.H. Frederik FALKENBURG
  • T cell receptors directed against Bob1 and uses thereof
    Patent number: 10189880
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: January 29, 2019
    Assignee: LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Mirjam H. M. Heemskerk, J. H. Frederik Falkenburg
  • T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF
    Publication number: 20160263155
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against the Preferentially Expressed Antigen of Melanoma (PRAME). Provided are methods for treating hyperproliferative diseases by inducing an immune response against PRAME antigen; the immune response may be induced by specifically targeting PRAME-expressing cells using T cell receptors directed against PRAME.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 15, 2016
    Inventors: Mirjam H.M. HEEMSKERK, J.H. Frederik FALKENBURG
  • T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF
    Publication number: 20160129094
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 12, 2016
    Inventors: Mirjam H.M. HEEMSKERK, J.H. Frederik Falkenburg